Related Experiment Video

Updated: Apr 27, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

8.9K

Phosphoinositide 3-kinase inhibitors in lymphoma

Emily Curran1, Sonali M Smith

  • 1Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.

Current Opinion in Oncology
|July 16, 2014
PubMed
Abstract

Insights

Targeting the phosphoinositide 3-kinase (PI3K) pathway with novel inhibitors shows promise for treating lymphomas. Clinical data indicate significant efficacy for PI3K inhibitors in lymphoid malignancies, paving the way for future research.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • The phosphoinositide 3-kinase (PI3K) pathway, including Akt and mTOR, is frequently dysregulated in various human cancers.
  • Hematologic malignancies, particularly lymphomas, are known to be influenced by aberrant PI3K pathway signaling.

Purpose of the Study:

  • To review current clinical data on PI3K inhibitors in lymphoid malignancies.
  • To discuss the efficacy and future directions of PI3K-targeted therapies in lymphoma treatment.

Main Methods:

  • Review of emerging clinical trial data and published literature on PI3K inhibitors in lymphoma.
  • Analysis of the therapeutic potential of specific PI3K inhibitors, including idelalisib and IPI-145.

Main Results:

  • The PI3Kδ inhibitor, idelalisib, has demonstrated efficacy as a monotherapy and in combination regimens for lymphoma.
  • IPI-145, a dual PI3Kδ/γ inhibitor, has shown positive results, with ongoing clinical trials.
  • Several other PI3K inhibitors are in various stages of clinical development.

Conclusions:

  • The PI3K pathway is a critical target in the pathogenesis of lymphoma.
  • Targeting the PI3K pathway with specific inhibitors offers a promising therapeutic strategy for lymphoid malignancies.

More Related Videos

Radiolabeling and Quantification of Cellular Levels of Phosphoinositides by High Performance Liquid Chromatography-coupled Flow Scintillation10:52

Radiolabeling and Quantification of Cellular Levels of Phosphoinositides by High Performance Liquid Chromatography-coupled Flow Scintillation

Published on: January 6, 2016

9.8K
Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

7.9K

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K